Abstract 7344: Role of ubiquitin receptor ADRM1 (Rpn13) in prostate cancer

Abstract

Abstract Adhesion-regulating molecule 1 (ADRM1)/Rpn13 is a component of the 19S regulatory subunit of the 26S proteasome [1]. ADRM1 plays a crucial role in the recognition of polyubiquitinated substrates of the proteasome and their subsequent deubiquitination and degradation [2]. ADRM1 transcript levels are commonly upregulated in diverse tumor types [3]. The androgen receptor (AR) plays a predominant role in prostate cancer (PCa) pathology. In this study, we investigated the expression of ADRM1/Rpn13 in different stages of prostate cancer and its association with AR expression. TCGA data from UALCAN was used for understanding ADRM1 expression on different stages of diseases and single-cell RNA-sequencing data of prostate cancer cell line was obtained from Prostate Cancer Atlas. TCGA (cell, 2015) data set was used for investigating the correlation between ADRM1 and AR by using R programming. Our study from the TCGA dataset reveals that ADRM1 expression increased significantly with the aggressiveness of prostate cancer (increase consistently with the Gleason score) from the TCGA dataset. We analyzed ADRM1 and AR expression in different prostate cancer cell lines and obtained that ADRM1 expressed significantly higher in prostate cancer cell lines which had lower AR expression. TCGA (cell, 2015) dataset indicated a negative correlation between ADRM1 and AR expression in prostate cancer. Our preliminary analysis indicated that ADRM1 inhibitor might be a potential therapeutic option for AR-independent prostate cancer. Citation Format: Shahjalal Chowdhury, Honghe Wang, Chitra Nayak, Balasubramanyam Karanam. Role of ubiquitin receptor ADRM1 (Rpn13) in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7344.